Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P41 versus US-licensed Prolia in postmenopausal osteoporosis
2020-005974-91Phase 3Completed
- Sponsor
- Celltrion
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis comparing CT-P41 with US-licensed Prolia (2 arms). Primary endpoint: Percent change from baseline in lumbar spine bone mineral density at Week 52. Started Mar 2021; status: completed.
02
Drugs
denosumab-nxxpdenosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2020-005974-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005974-91.